Microbiome Compositions for Subject-Specific Metabolome Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies lack effective methods to modulate the metabolome of subjects to identify and treat diseases, disorders, or conditions associated with specific metabolite levels, and there is a need for diagnostic tools to assess individual metabolome differences.
Innovation Solution
Compositions comprising microbial strains and lipopolysaccharides are administered to subjects to modulate metabolite levels, allowing for the characterization and treatment of diseases or conditions by evaluating metabolome changes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If compositions comprising microbial strains and lipopolysaccharides are administered to subjects, then metabolite levels are modulated and diagnostic capability is improved, but device complexity and treatment protocol complexity increase
Solution Approach 1:
The patent uses microbial compositions (containing microbial strains and lipopolysaccharides) as intermediary agents to modulate the subject's metabolome. These compositions serve as mediators between the administered treatment and the metabolic changes, enabling indirect modulation of metabolite levels while providing diagnostic information about the subject's metabolic state and disease susceptibility
Solution Approach 2:
The patent employs preliminary metabolome assessment to identify subjects with abnormal metabolite levels before administering microbial compositions. This preliminary action allows for personalized treatment protocols tailored to each subject's specific metabolic profile, improving diagnostic precision while optimizing treatment complexity by targeting only those who need it
2Measurement precision
If subject-specific metabolome modulation is implemented, then personalized diagnostic capability is improved, but loss of time for assessment and treatment increases
Solution Approach 1:
The patent creates a metabolic profile 'copy' or signature for each subject by measuring metabolite levels in biological samples. This metabolic copy serves as a surrogate marker that rapidly characterizes the subject's metabolic state and disease risk without requiring time-consuming direct observation of disease development, enabling quick personalized assessment and treatment planning
Data Source
AI summary
Methods and uses of compositions (e.g. comprising one or more microbial strains) are disclosed.